new data submitted of a 2nd assay shows enhanced potency compared to prochymal. hopefully this reassures fda the study was adequate and controlled. meeting next month.
"very encouraging" meeting re hfref. nothing else said apart from waiting on minutes.
anticipate further reduction in spend and funded to complete enrollment in back and adult gvhd.
Ann: Mesoblast 2024 Half Year Financial Results Webcast, page-53
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.000(0.00%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2263 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.43 | 6118 | 1 |
View Market Depth
| Last trade - 09.57am 12/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
Day chart unavailable